Join
Live feed
·
PRReleasevia Quantisnow
Repare Therapeutics Inc. logo

Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor

ByQuantisnow·Wall Street's wire, on your screen.
RPTX· Repare Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RPTX (Repare Therapeutics Inc.) and more on Quantisnow.